期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 60, 期 7, 页码 4355-4360出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00405-16
关键词
-
资金
- Allergan
A total of 7,272 unique patient clinical isolates were collected from 71 U.S. medical centers from patients with urinary tract infections in 2012 to 2014 and tested for susceptibility to ceftazidime-avibactam and comparators by broth microdilution methods. Ceftazidime-avibactam inhibited >99.9% of all Enterobacteriaceae at the susceptible breakpoint of <= 8 mu g/ml (there were only three nonsusceptible strains). Ceftazidime-avibactam was also active against Pseudomonas aeruginosa isolates (MIC50, 2 mu g/ml; MIC90, 4 mu g/ml; 97.7% susceptible), including many isolates not susceptible to meropenem, ceftazidime, and/or piperacillin-tazobactam.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据